Approved indication: In the United States, Arikayce is FDA-approved, under a limited-population indication, to be used with a combination antibacterial regimen to treat adults with refractory Mycobacterium avium complex (MAC) lung disease who remain culture-positive after at least 6 months of guideline-based therapy and who have limited or no alternative treatment options.

Off-label uses: Outside this setting, inhaled amikacin liposome has mainly been studied for other nontuberculous mycobacterial lung infections (such as Mycobacterium abscessus), but these uses are not FDA-approved and remain investigational or specialized off-label therapy with more limited and evolving evidence; they are generally reserved for expert centers.

Efficacy expectations:

• Benefits usually appear gradually over months; some patients have sputum cultures turn negative within the first 1–3 months after adding Arikayce to their regimen.
• In the Phase 3 CONVERT trial in refractory MAC lung disease, about 29% of patients receiving Arikayce plus background multidrug therapy achieved culture conversion by month 6 compared with about 9% on background therapy alone, and a meaningful fraction of responders maintained culture negativity for at least 12 months and several months after stopping treatment.
• Patients may experience improvements in symptoms such as cough, sputum production, and fatigue and, in some studies, better respiratory quality-of-life scores, although not all functional measures (like walking distance) improved clearly.
• Compared with intravenous aminoglycosides, Arikayce delivers high drug levels directly in the lungs with lower average blood levels, which may reduce but does not eliminate systemic risks such as hearing loss and kidney damage while adding inhalation-related respiratory side effects.

Typical dosing: For adults with refractory MAC lung disease, the usual dose is the entire contents of one 590 mg/8.4 mL vial inhaled once daily using only the Lamira Nebulizer System, always as part of a multidrug antibiotic regimen.

How to take it: If you use a short-acting bronchodilator, take that first as directed, then nebulize Arikayce while sitting upright and breathing calmly through the mouthpiece until the nebulizer chamber is empty; do not swallow the solution, do not mix it with other medicines in the nebulizer, and follow the manufacturer’s instructions for preparing, using, and cleaning the Lamira device.

Special instructions: Use Arikayce at about the same time each day, make sure each vial has been brought to room temperature and shaken well before use, and follow the recommended schedule for replacing nebulizer components; contact your clinician if you have significant cough, wheeze, or coughing up blood during or after a dose.

Missed doses and overdose: If you miss a dose, skip it and take your next dose at the usual time without doubling up; if you accidentally use more than prescribed or have symptoms of overdose, stop the medicine and seek urgent medical advice or contact a poison control center, since systemic aminoglycoside exposure can affect the kidneys and ears.

Common side effects:

• Very common effects include hoarse voice or voice changes, cough, throat or upper airway irritation, shortness of breath or chest tightness, fatigue, diarrhea, nausea, headache, low-grade fever, and weight loss; these often begin early in therapy and are usually mild to moderate.
• Many patients in clinical trials experienced at least one respiratory side effect, but most were managed with dose interruption, bronchodilators, or other supportive care rather than permanent discontinuation.

Serious or rare adverse effects requiring urgent medical attention:

• Hypersensitivity pneumonitis (sudden or rapidly worsening cough, fever, shortness of breath, or diffuse chest tightness).
• Coughing up blood (hemoptysis), severe bronchospasm or wheezing, or marked worsening of underlying lung disease.
• Hearing loss, ringing or buzzing in the ears, a feeling of fullness in the ears, or new balance problems or spinning sensations.
• Signs of kidney injury such as decreased urine output, ankle or leg swelling, or unexplained fatigue.
• Severe allergic reactions with rash, hives, facial, lip, tongue, or throat swelling, or difficulty breathing.

Warnings and precautions: Arikayce carries a boxed warning for increased respiratory adverse reactions (hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease), is contraindicated in patients with known hypersensitivity to aminoglycosides, and should be used with great caution in people with kidney disease, prior hearing or balance problems, or neuromuscular disorders such as myasthenia gravis; it is not approved for use in children, and in pregnancy or breastfeeding the potential for aminoglycoside-related harm to the baby (including irreversible congenital deafness with systemic exposure) must be weighed carefully against the need to treat refractory disease.

Relative safety compared with other options: Compared with intravenous aminoglycosides, inhaled Arikayce generally results in lower systemic drug levels and may lessen but does not remove the risks of ototoxicity and nephrotoxicity, while adding local respiratory effects from inhalation that need monitoring.

Reporting side effects and safety updates: Suspected side effects can be reported to the FDA MedWatch program (online or via 1-800-FDA-1088) or to the manufacturer’s medical information line, and the latest safety communications and full prescribing information are available through the FDA and official Arikayce websites.

Drug and supplement interactions:

• Avoid using Arikayce with other medicines that can damage the ears, kidneys, or nerves—such as other aminoglycoside antibiotics, certain chemotherapy agents (for example cisplatin), or intravenous amphotericin B—unless your specialist considers it essential and monitors you closely.
• Certain diuretics, including furosemide, ethacrynic acid, intravenous mannitol, and high-dose urea, can increase aminoglycoside toxicity and are generally avoided in combination with Arikayce.
• No specific interactions with foods are known, and common vitamins or herbal supplements have not shown clear interactions, but you should give your care team a complete list of all prescription, over-the-counter, and herbal products you use.
• Alcohol has no direct interaction with Arikayce but may worsen dizziness or balance problems in people vulnerable to ototoxicity and can aggravate some respiratory symptoms.

Precautions and conditions requiring extra care:

• Kidney disease, prior hearing loss, ringing in the ears, balance problems, or past aminoglycoside toxicity increase the risk of ototoxicity and nephrotoxicity and warrant closer monitoring or dose adjustment.
• Asthma, COPD, or other hyperreactive airway diseases increase the risk of bronchospasm; pretreatment with a short-acting bronchodilator and careful observation during inhalation are often recommended.
• Neuromuscular disorders such as myasthenia gravis can be worsened by aminoglycosides, which may aggravate muscle weakness; use only under specialist supervision.
• Arikayce is not approved for children and adolescents, and its safety and efficacy in patients under 18 years are not established.
• In pregnancy and breastfeeding, potential fetal or infant risks (particularly hearing damage associated with systemic aminoglycosides) must be balanced against the seriousness of refractory MAC lung disease, and decisions should be made with a specialist.

Monitoring needs: During treatment, your care team may periodically check kidney function tests, assess hearing and balance, monitor respiratory status for bronchospasm or hypersensitivity pneumonitis, and obtain sputum cultures to track response, adjusting therapy if toxicity or lack of benefit becomes apparent.

Q: What is Arikayce used for?
A: Arikayce is an inhaled antibiotic used together with other medicines to treat adults who still have Mycobacterium avium complex (MAC) lung disease after at least six months of standard multidrug therapy and who have limited or no other treatment options.

Q: How long does it take for Arikayce to start working?
A: Some patients show negative sputum cultures or symptom improvement within the first few months, but treatment usually continues for many months and is guided by repeated sputum cultures and how you feel.

Q: Will Arikayce cure my MAC lung disease?
A: Arikayce can significantly increase the chance of clearing MAC from sputum when added to background therapy, but not everyone converts to negative cultures, and even responders may need long courses of treatment and close follow-up for relapse.

Q: Is Arikayce safer than intravenous amikacin?
A: Inhaled Arikayce generally produces lower levels of amikacin in the bloodstream than typical intravenous dosing, which may reduce but does not eliminate the risks of hearing loss and kidney damage, and it adds respiratory side effects related to inhalation.

Q: What should I do if Arikayce makes me cough or wheeze?
A: Mild cough or throat irritation is common, but if you have significant wheezing, chest tightness, or trouble breathing, stop the treatment, use your rescue inhaler if prescribed, and contact your clinician promptly or seek urgent care if symptoms are severe.

Q: Can I use Arikayce with my other inhaled medications?
A: Many patients use Arikayce along with bronchodilators and other inhaled therapies, but you should not mix other medicines in the same nebulizer, and you should follow your clinician’s instructions on the order and timing of each inhaled medicine.

Storage: Store Arikayce vials in the refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton and do not freeze; if needed, vials may be kept at room temperature (up to 77°F / 25°C) for up to 4 weeks, after which any unused vials must be discarded.

Before use: Remove a vial from the refrigerator about 45 minutes before your dose so it can warm to room temperature, shake it well as directed, and use the entire contents right away; discard the opened vial immediately after each treatment.

Disposal: Keep vials out of the reach of children and pets, do not flush them or pour leftover medicine down the drain, and use a community medicine take-back program or follow your pharmacist’s or local waste authority’s instructions for safe household disposal.